Chronic myeloid leukemia: past, present, future [PDF]
Einstein (São Paulo), 2011 The discovery of the Philadelphia chromosome in 1960, and of theBCR-ABL oncogene in 1984, enabled the development in subsequentyears of a targeted therapy that revolutionized the treatment of chronic myeloid leukemia, thus changing its natural history ...
Patricia Weinschenker Bollmann +1 more
doaj +4 more sources
Acta Médica Portuguesa, 2019 Until recently, the main goal of chronic myeloid leukemia therapy was disease control with the best overall survival, which required lifelong treatment.
Antonio Almeida +10 more
doaj +1 more source
Imatinib and nilotinib inhibit hematopoietic progenitor cell growth, but do not prevent adhesion, migration and engraftment of human cord blood CD34+ cells. [PDF]
PLoS ONE, 2012 BACKGROUND: The availability of tyrosine kinase inhibitors (TKIs) has considerably changed the management of Philadelphia chromosome positive leukemia.
Ludovic Belle +6 more
doaj +1 more source
Chronic myeloid leukemia-clinical, experimental and health economic studies with special reference to imatinib treatment [PDF]
, 2013 CML is a malignant disease that originates in the bone marrow stem cell, carrying the Philadelphia chromosome with the BCR-ABL fusion gene. This gene translates into an active tyrosine kinase, Bcr-Abl, affecting hematopoiesis, particularly resulting in ...
Ohm, Lotta
core +1 more source
Pharmaceutical care and home delivery of medication to patients with chronic myeloid leukemia [PDF]
Farmacia Hospitalaria, 2015 Objectives: To describe the implementation of a new model face to face and remote pharmaceutical care with home delivery of tyronsine kinase inhibitors medicines for patients with chronic myeloid leukemia.
Begoña San José Ruiz +2 more
doaj +1 more source
Review of clinical, cytogenetic, and molecular aspects of Ph-negative CML [PDF]
, 1991 Between 1985 and 1989, many cases of Philadelphia (Ph) chromosome negative chronic myelogenous leukemia (CML) were reported. For this review, the following selection criteria were used: the original articles on Ph-negative cases should provide clinical ...
Grosveld, G.C. (Gerard) +2 more
core +1 more source
Novel clinical trial designs emerging from the molecular reclassification of cancer
CA: A Cancer Journal for Clinicians, Volume 75, Issue 3, Page 243-267, May/June 2025.Abstract Next‐generation sequencing has revealed the disruptive reality that advanced/metastatic cancers have complex and individually distinct genomic landscapes, necessitating a rethinking of treatment strategies and clinical trial designs. Indeed, the molecular reclassification of cancer suggests that it is the molecular underpinnings of the disease,
Mina Nikanjam +4 more
wiley +1 more source
Biomolecular Concepts, 2021 The BCR-ABL oncogene is a tyrosine kinase gene that is over-expressed in CML. It inhibits the TGF-β1 signaling pathway. Due to resistance of cells to the tyrosine kinase inhibitor, STI-571, the combined effect of STI-571 and TGF-β1 on K562 cells was ...
Bakhshayesh Masoome +3 more
doaj +1 more source
Detection of BCR-ABL kinase domain mutations in CD34+ cells from newly diagnosed chronic phase CML patients and their association with imatinib resistance [PDF]
, 2011 BCR-ABL kinase domain (KD) mutations, the most common cause of imatinib resistance, are infrequently detected in newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML) patients.
Aamer Aleem +19 more
core +1 more source
Clinical implications of discordant early molecular responses in CML patients treated with imatinib [PDF]
, 2019 A reduction in BCR-ABL1/ABL1IS transcript levels to <10% after 3 months or <1% after 6 months of tyrosine kinase inhibitor therapy are associated with superior clinical outcomes in chronic myeloid leukemia (CML) patients.
Accurso V. +23 more
core +1 more source